NEW YORK (GenomeWeb) – AstraZeneca today announced a collaboration with Roche to develop a companion diagnostic for AstaZeneca's investigational compound for non-small cell lung cancer.

The test will be directed at AZD9291 and will be developed to identify epidermal growth factor receptor mutations in tumor tissue as well as plasma samples from patients with NSCLC. It also will be designed to optimize the clinical development of AZD9291 for patients who are resistant to first-generation EGFR tyrosine kinase inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.